Results of a randomized, double-blind, active-controlled clinical trial with propiverine extended release 30 mg in patients with overactive bladder

详细信息    查看全文

• 作者：Jing Leng ; Limin Liao ; Ben Wan ; Chuanjun Du ; Wei Li ; Keji Xie ; Zhoujun Shen ; Zhuoqun Xu ; Shiliang Wu ; Zujun Fang ; Lulin Ma ; Shaomei Han ; Cornelia Feustel ; Yong Yang and Helmut Madersbacher
• 刊名：BJU International
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：119
• 期：1
• 页码：148-157
• 全文大小：366K
• ISSN：1464-410X

文摘

To compare the efficacy and safety of the 30 mg extended release (ER) formulation of propiverine hydrochloride with the 4 mg ER formulation of tolterodine tartrate in patients with overactive bladder (OAB) in a non-inferiority trial.